MUSE-XAE: MUtational Signature Extraction with EXplainable AutoEncoder Enhances Tumour Types Classification

Overview

Journal Bioinformatics

Publisher Oxford University Press

Specialty Biology

Date 2024 May 16

PMID 38754097

Authors

Corrado Pancotti

Cesare Rollo

Francesco Codice

Giovanni Birolo

Piero Fariselli

Tiziana Sanavia

Affiliations

Soon will be listed here.

Abstract

Motivation: Mutational signatures are a critical component in deciphering the genetic alterations that underlie cancer development and have become a valuable resource to understand the genomic changes during tumorigenesis. Therefore, it is essential to employ precise and accurate methods for their extraction to ensure that the underlying patterns are reliably identified and can be effectively utilized in new strategies for diagnosis, prognosis, and treatment of cancer patients.

Results: We present MUSE-XAE, a novel method for mutational signature extraction from cancer genomes using an explainable autoencoder. Our approach employs a hybrid architecture consisting of a nonlinear encoder that can capture nonlinear interactions among features, and a linear decoder which ensures the interpretability of the active signatures. We evaluated and compared MUSE-XAE with other available tools on both synthetic and real cancer datasets and demonstrated that it achieves superior performance in terms of precision and sensitivity in recovering mutational signature profiles. MUSE-XAE extracts highly discriminative mutational signature profiles by enhancing the classification of primary tumour types and subtypes in real world settings. This approach could facilitate further research in this area, with neural networks playing a critical role in advancing our understanding of cancer genomics.

Availability And Implementation: MUSE-XAE software is freely available at https://github.com/compbiomed-unito/MUSE-XAE.

References

Tate J, Bamford S, Jubb H, Sondka Z, Beare D, Bindal N . COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2018; 47(D1):D941-D947. PMC: 6323903. DOI: 10.1093/nar/gky1015. View

Secrier M, Li X, de Silva N, Eldridge M, Contino G, Bornschein J . Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet. 2016; 48(10):1131-41. PMC: 5957269. DOI: 10.1038/ng.3659. View

Degasperi A, Amarante T, Czarnecki J, Shooter S, Zou X, Glodzik D . A practical framework and online tool for mutational signature analyses show inter-tissue variation and driver dependencies. Nat Cancer. 2020; 1(2):249-263. PMC: 7048622. DOI: 10.1038/s43018-020-0027-5. View

Wojtowicz D, Hoinka J, Amgalan B, Kim Y, Przytycka T . RepairSig: Deconvolution of DNA damage and repair contributions to the mutational landscape of cancer. Cell Syst. 2021; 12(10):994-1003.e4. DOI: 10.1016/j.cels.2021.07.004. View

Islam S, Diaz-Gay M, Wu Y, Barnes M, Vangara R, Bergstrom E . Uncovering novel mutational signatures by extraction with SigProfilerExtractor. Cell Genom. 2022; 2(11):None. PMC: 9646490. DOI: 10.1016/j.xgen.2022.100179. View

Vohringer H, Van Hoeck A, Cuppen E, Gerstung M . Learning mutational signatures and their multidimensional genomic properties with TensorSignatures. Nat Commun. 2021; 12(1):3628. PMC: 8206343. DOI: 10.1038/s41467-021-23551-9. View

Schulze K, Imbeaud S, Letouze E, Alexandrov L, Calderaro J, Rebouissou S . Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015; 47(5):505-511. PMC: 4587544. DOI: 10.1038/ng.3252. View

Pancotti C, Rollo C, Birolo G, Benevenuta S, Fariselli P, Sanavia T . Unravelling the instability of mutational signatures extraction archetypal analysis. Front Genet. 2023; 13:1049501. PMC: 9846778. DOI: 10.3389/fgene.2022.1049501. View

Alexandrov L, Nik-Zainal S, Wedge D, Aparicio S, Behjati S, Biankin A . Signatures of mutational processes in human cancer. Nature. 2013; 500(7463):415-21. PMC: 3776390. DOI: 10.1038/nature12477. View

10.

Kiciatovas D, Guo Q, Kailas M, Pesonen H, Corander J, Kaski S . Identification of multiplicatively acting modulatory mutational signatures in cancer. BMC Bioinformatics. 2022; 23(1):522. PMC: 9724449. DOI: 10.1186/s12859-022-05060-8. View

11.

Schumann F, Blanc E, Messerschmidt C, Blankenstein T, Busse A, Beule D . SigsPack, a package for cancer mutational signatures. BMC Bioinformatics. 2019; 20(1):450. PMC: 6720940. DOI: 10.1186/s12859-019-3043-7. View

12.

Lal A, Liu K, Tibshirani R, Sidow A, Ramazzotti D . De novo mutational signature discovery in tumor genomes using SparseSignatures. PLoS Comput Biol. 2021; 17(6):e1009119. PMC: 8270462. DOI: 10.1371/journal.pcbi.1009119. View

13.

Degasperi A, Zou X, Amarante T, Martinez-Martinez A, Koh G, Dias J . Substitution mutational signatures in whole-genome-sequenced cancers in the UK population. Science. 2022; 376(6591. PMC: 7613262. DOI: 10.1126/science.abl9283. View

14.

Maura F, Degasperi A, Nadeu F, Leongamornlert D, Davies H, Moore L . A practical guide for mutational signature analysis in hematological malignancies. Nat Commun. 2019; 10(1):2969. PMC: 6611883. DOI: 10.1038/s41467-019-11037-8. View

15.

Alexandrov L, Nik-Zainal S, Wedge D, Campbell P, Stratton M . Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 2013; 3(1):246-59. PMC: 3588146. DOI: 10.1016/j.celrep.2012.12.008. View

16.

Ma J, Setton J, Lee N, Riaz N, Powell S . The therapeutic significance of mutational signatures from DNA repair deficiency in cancer. Nat Commun. 2018; 9(1):3292. PMC: 6098043. DOI: 10.1038/s41467-018-05228-y. View

17.

. Pan-cancer analysis of whole genomes. Nature. 2020; 578(7793):82-93. PMC: 7025898. DOI: 10.1038/s41586-020-1969-6. View

18.

Svensson V, Gayoso A, Yosef N, Pachter L . Interpretable factor models of single-cell RNA-seq via variational autoencoders. Bioinformatics. 2020; 36(11):3418-3421. PMC: 7267837. DOI: 10.1093/bioinformatics/btaa169. View

19.

Fischer A, Illingworth C, Campbell P, Mustonen V . EMu: probabilistic inference of mutational processes and their localization in the cancer genome. Genome Biol. 2013; 14(4):R39. PMC: 3663107. DOI: 10.1186/gb-2013-14-4-r39. View

20.

Koh G, Degasperi A, Zou X, Momen S, Nik-Zainal S . Mutational signatures: emerging concepts, caveats and clinical applications. Nat Rev Cancer. 2021; 21(10):619-637. DOI: 10.1038/s41568-021-00377-7. View